
We claim:

1. An aqueous formulation comprising a conjugate comprising a compound linked to a polypeptide, wherein the compound comprises the structure:



wherein ≡ is a double bond or a single bond;

wherein when ≡ is a double bond, X and Y are each CH; and

when ≡ is a single bond, one of X and Y is CH_2 and the other is CH_2, O, or NH; and the structure is optionally substituted at any position other than the $-NH_2$;

wherein the pH of the formulation ranges from about 4.5 to about 5.2; and

wherein the polypeptide is an antibody that binds to a tumor associated antigen selected from HER2, Nectin-4, ASGR1, mesothelin, PSMA, rsPSMA, TROP2, LIV-1, MUC16, CEACAM1, CEACAM3, CEACAM4, CEACAM5, CEACAM6, CEACAM7, CEACAM8, CEACAM16, CEACAM18, CEACAM19, CEACAM20, CEACAM21, URLC10, NY-ESO-1, GAA, OFA, cyclin B1, WT-1, CEF, VEGRR1, VEGFR2, TTK, MUC1, HPV16E7, CEA, IMA910, KOC1, SL-701, MART-1, gp100, tyrosinase, GSK2302050A, survivin, MAGE-3.1, MAGE-10.A2, OVA BiP, gp209-2M, melan-A, NA17.A2, KOC1, CO16, DEPDC1, MPHOSPH1, MAGE12, ONT-10, GD2L, GD3L, GSK2302032A, URLC10, CDCA1, TF, PSA, MUC-2, TERT, HPV16, HPV18, STF-II, G17DT, ICT-107, Dex2, hTERT, PAP, tyrosinase related peptide 2 (TRP2), and LRRC15.

2. The aqueous formulation of claim 1, wherein the pH of the formulation ranges from 4.7 to 5.0.

3. The aqueous formulation of claim 1, wherein the formulation further comprises at least one buffering agent selected from histidine, citrate, aspartate, acetate, phosphate, lactate, tromethamine, gluconate, glutamate, tartrate, succinate, malic acid, fumarate, α-ketoglutarate, and combinations thereof.

4. The aqueous formulation of claim 3, wherein the at least one buffering agent comprising histidine and aspartate.

5. The aqueous formulation of claim 4, wherein the total concentration of histidine and aspartate ranges from about 15mM to about 25mM.

6. The aqueous formulation of claim 3, wherein the aqueous formulation further comprises at least one lyoprotectant selected from sucrose, arginine, glycine, sorbitol, glycerol, trehalose, dextrose, alpha-cyclodextrin, hydroxypropyl beta-cyclodextrin, hydroxypropyl

gamma-cyclodextrin, proline, methionine, albumin, mannitol, maltose, dextran, and combinations thereof.

7. The aqueous formulation of claim 6, wherein the at least one lyoprotectant comprises sucrose.

8. The aqueous formulation of claim 7, wherein the concentration of the sucrose is about 7% to about 9%.

9. The aqueous formulation of claim 6, wherein the aqueous formulation further comprises at least one surfactant.

10. The aqueous formulation of claim 9, wherein the at least one surfactant is selected from polysorbate 80, polysorbate 20, poloxamer 88, and combinations thereof.

11. The aqueous formulation of claim 10, wherein the at least one surfactant comprises polysorbate 80.

12. The aqueous formulation of claim 11, wherein the concentration of the polysorbate 80 is about 0.01% to about 0.05%.

13. The aqueous formulation of claim 1, wherein the concentration of the conjugate is about 70 mg/mL to about 100 mg/mL.

14. The aqueous formulation of claim 1, wherein the antibody is an anti-HER2 antibody.


15. The aqueous formulation of claim 1, wherein the antibody is an anti-Nectin-4 antibody.

16. The aqueous formulation of claim 1, wherein the antibody is an anti-ASGR1 antibody.

17. The aqueous formulation of claim 1, wherein the antibody is an anti-mesothelin antibody.

18. The aqueous formulation of claim 1, wherein the compound is a TLR8 agonist.

19. The aqueous formulation of claim 1, wherein the conjugate is represented by Formula (I):



(I);

wherein:

A is the polypeptide,


L is a linker;


D_x is the compound;


n is selected from 1 to 20; and


z is selected from 1 to 20.


20. The aqueous formulation of claim 19, wherein L and Dx together have a structure selected from:














,




,




,





,





,













,



,

and




,

and salts thereof,

wherein the RX^* is a bond, a succinimide moiety, or a hydrolyzed succinimide moiety bound to a residue of a polypeptide,

wherein  on RX* represents the point of attachment to the residue of the polypeptide.

21. A lyophilized composition comprising a conjugate comprising a compound linked to a polypeptide, wherein the compound comprises the structure:



wherein is a double bond or a single bond;

wherein when is a double bond, X and Y are each CH; and

when is a single bond, one of X and Y is CH_2 and the other is CH_2, O, or NH; and

the structure is optionally substituted at any position other than the $-NH_2$;

wherein upon reconstitution of the lyophilized composition in water to form an aqueous formulation, the pH of the aqueous formulation ranges from about 4.5 to about 5.2; and

wherein the polypeptide is an antibody that binds to a tumor associated antigen selected from HER2, Nectin-4, ASGR1, mesothelin, PSMA, rsPSMA, TROP2, LIV-1, MUC16, CEACAM1, CEACAM3, CEACAM4, CEACAM5, CEACAM6, CEACAM7, CEACAM8, CEACAM16, CEACAM18, CEACAM19, CEACAM20, CEACAM21, URLC10, NY-ESO-1, GAA, OFA, cyclin B1, WT-1, CEF, VEGRR1, VEGFR2, TTK, MUC1, HPV16E7, CEA, IMA910, KOC1, SL-701, MART-1, gp100, tyrosinase, GSK2302050A, survivin, MAGE-3.1, MAGE-10.A2, OVA BiP, gp209-2M, melan-A, NA17.A2, KOC1, CO16, DEPDC1, MPHOSPH1, MAGE12, ONT-10, GD2L, GD3L, GSK2302032A, URLC10, CDCA1, TF, PSA, MUC-2, TERT, HPV16, HPV18, STF-II, G17DT, ICT-107, Dex2, hTERT, PAP, tyrosinase related peptide 2 (TRP2), and LRRC15.

22. Use of a therapeutically effective amount of the aqueous formulation of claim 1 in the manufacture of a medicament for treating a cancer in a subject.